Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

Abstract Background Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism with the anti-inflammatory and anti-fibr...

Full description

Bibliographic Details
Main Authors: Andrea Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, Robert Crooker, Dianna Lundberg, Niksa Kastrapeli, Brian Pescatore, Alla Romashko, John Dumas, Robert Comeau, Angela Norton, Jing Pan, Haojing Rong, Katayoun Derakhchan, David E. Ehmann
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Skeletal Muscle
Subjects:
Myostatin
Activin a
Follistatin
Hypertrophy
Fibrosis
mdx
Online Access:http://link.springer.com/article/10.1186/s13395-018-0180-z

Internet

http://link.springer.com/article/10.1186/s13395-018-0180-z

Similar Items